Last reviewed · How we verify
Iron Glycinate (FERROUS BISGLYCINATE)
Iron Glycinate works by providing the body with a readily available form of iron that can be easily absorbed and utilized to produce hemoglobin.
Ferrous Bisglycinate, an iron supplement marketed for contraception, holds a unique position in the market due to its specific indication. Its key strength lies in its mechanism of action, providing a readily available form of iron that enhances absorption and utilization for hemoglobin production. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | FERROUS BISGLYCINATE |
|---|---|
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Mechanism of action
Think of it like a key that unlocks the body's ability to make red blood cells. When we're deficient in iron, our bodies can't make enough hemoglobin, which carries oxygen to our cells. Iron Glycinate helps fill this gap by providing the iron needed to produce healthy red blood cells.
Approved indications
- Contraception
Boxed warnings
- WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke [see Contraindications ( 4 )] . WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full Prescribing Information for complete Boxed Warning Minzoya is contraindicated in women over 35 years old who smoke. ( 4 ) Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. ( 4 )
Common side effects
- Allergic sensitization
Key clinical trials
- Efficacy and Adverse Side Effects of Two Forms of Iron in Pregnancy (NA)
- Glycoprotein Matrix-Bound Iron Improves Iron Absorption (NA)
- Potential Harms of Untargeted Iron Supplementation in Cambodia Where Iron Deficiency is Not the Cause of Anemia (PHASE4)
- Baby Iron Bioavailability Study (NA)
- Iron Sucrose Versus Ferrous Bis-glycinate for Treatment of Iron Deficiency Anemia (PHASE3)
- A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate. (PHASE3)
- Efficacy of Iron Bisglycinate in Treatment of Iron Deficiency Anemia in Pregnant Women (PHASE3)
- A Study to Compare the Gastrointestinal Tolerability of Ferrochel®, Sumalate®,Ferrous Fumarate, Ferrous Sulfate, Ferric Glycinate, and Placebo (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iron Glycinate CI brief — competitive landscape report
- Iron Glycinate updates RSS · CI watch RSS